Integrating AI in Medicinal Chemistry for Accelerated Drug Discovery: A Comprehensive SAR (CSAR) Optimization...

Developing potent, selective small-molecule inhibitors remains a major challenge in drug discovery. ALDH3A1, a detoxifying aldehyde dehydrogenase isoform implicated in cancer and neurodegeneration, is a promising yet underexplored therapeutic target. To accelerate inhibitor optimization, we developed an AI-guided, reaction-based hit-to-lead workflow combining sequential reaction enumeration, pharmacophore-informed docking, and predictive modeling to support scalable SAR expansion. Applied to ALDH3A1, two rounds of enumeration using Enamine building blocks generated about 250,000 virtual analogues. Combined deep learning and docking-based triage prioritized 150 compounds for synthesis, leading to a roughly 1,000-fold improvement in biochemical potency from 1.41 μM to 1 nM for NCATS-SM0707, together with 4 nM cellular activity for NCATS-SM0708. Crucially, this methodology can be expanded by applying various chemical reactions at different positions. This study highlights CSAR as a scalable, generalizable complementary strategy to accelerate hit optimization through reaction-based enumeration and AI-guided prioritization of larger synthetically accessible chemical space.